Ark Therapeutics partnership achieves first milestone

published 4 January 2012

Specialist healthcare group, Ark Therapeutics, and serious diseases therapies developer PsiOxus Therapeutics, said their partnership has successfully achieved its first milestone.

The firms have manufactured PsiOxus's colorectal cancer product, and as a result PsiOxus has initiated final pre-clinical toxicology studies of the product.

Martyn Williams, Chief Executive Officer of Ark said: "We are delighted that our early success with ColoAd1 will enable the development of this exciting product to move forward as planned and we look forward to continuing to provide full support to our partner as their programme moves into the clinic."